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Abstract
Background: Pregabalin is recommended as an adjuvant analgesic for neuropathic cancer-related pain, and may
be taken at all steps of the World Health Organization analgesic ladder. However, unlike opioids, pregabalin
treatments are limited to an oral administration route. If patients have oral feeding difficulties, it is not possible to
administer any drug as an adjuvant analgesic for neuropathic cancer-related pain. Therefore, the aim of the present
study was to clarify the problems of pain control after pregabalin discontinuation in terminally ill cancer patients.
Methods: Our subjects comprised cancer patients who died during their hospital stay and were referred between
April 2013 and October 2015 to the palliative care team of the 899-bed Cancer Hospital at the Nippon Medical
School Hospital in Japan. The medical records of each patient were retrospectively reviewed, and patient
characteristics were recorded.
Results: We obtained data on 183 patients during the study period. Thirty-eight (20.8 %) patients were treated with
pregabalin. Thirty-three (86.8 %) out of 38 patients were prescribed pregabalin for neuropathic cancer-related pain.
The incidence of bony metastases was significantly higher in patients administered pregabalin than in those not
taking the drug (non-pregabalin group 32.4 % vs pregabalin group 57.9 %). Pregabalin was ultimately discontinued
in all patients, with the main reason being oral feeding difficulties (81.6 %). After the discontinuation of pregabalin,
the amount of opioid drugs administered was increased in 56.5 % of patients with oral feeding difficulties.
Conclusion: Our results demonstrated that the amount of opioid drugs administered was increased in more than
50 % of patients following the discontinuation of pregabalin, and was repeatedly increased for some patients. A
new administration route is required for cancer patients unable to take oral medication.
Trial registration: UMIN000022507. May 28, 2016 retrospectively registered.
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Background
Pain occurs in approximately 30 % of all cancer patients,
and in 60–70 % and 75 % of advanced and terminally ill
cancer patients, respectively. Persistent pain is the most
common type of pain reported in cancer patients; 50 %
of patients have moderate or advanced pain, while 30 %
have advanced or unbearable pain [1, 2]. Since termin-
ally ill cancer patients have emotional distress and phys-
ical pain, palliative care incorporates the administration
of a number of different drugs including opioids,
antipyretic analgesics, and adjuvant analgesics.
Cancer cells in terminally ill cancer patients spread to
various sites. When metastasized cancer cells compress
nerve tissue, characteristic pain, such as electric shock-
like pain with tingling, develops. Pregabalin is recom-
mended as the first-line therapy in the guidelines for
neuropathic pain, is widely used as an adjuvant anal-
gesic for patients with neuropathic pain, and may be
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taken at all steps of the World Health Organization
analgesic ladder [3, 4].
However, unlike opioid drugs and antipyretic analge-
sics, pregabalin treatments are limited in Japan to an
oral administration route. If terminally ill patients de-
velop oral feeding difficulties, it is not possible to admin-
ister any drug as an adjuvant analgesic for neuropathic
cancer-related pain. Therefore, pain control has not yet
been established for terminally ill cancer patients with
oral feeding difficulties.
The aim of the present study was to clarify the prob-
lems of pain control after pregabalin discontinuation.
Therefore, we investigated the current status of pregaba-
lin treatments in terminally ill cancer patients.
Methods
Data sources and procedures
The method used in the present study was a chart
review. Subjects comprised patients with cancer who
were referred between April 1, 2013 and October 31,
2015 to the palliative care team of the 899-bed Cancer
Hospital at the Nippon Medical School Hospital in
Japan. Inclusion criteria were: a diagnosis of incurable
advanced cancer and patients who died during their
hospital stay at Nippon Medical School Hospital.
Demographic and patient clinical data
Information including age, sex, the date of admission,
date of death, primary cancer site, bone metastases, re-
quested reasons for palliative care, performance status
(PS) at the time of the palliative care intervention, and a
prescription for pregabalin was extracted from the elec-
tronic medical records of each patient.
The current status of pregabalin treatments
Information including the prescriber, reasons for the
prescription, initial dose, maintenance dose, administra-
tion period, weight, creatinine clearance (Ccr) calculated
from the Cockcroft-Gault formula, if pregabalin had
been discontinued, the reason for its discontinuation,
and the dose of opioid drugs before and after the discon-
tinuation of pregabalin was extracted from the electronic
medical records of patients prescribed pregabalin.
We investigated the dose of opioids administered be-
fore and after the discontinuation of pregabalin. The
doses of opioid drugs were converted to morphine-
equivalent dose. The half-life of pregabalin according to
renal function is 5–48 h, as stated on the package insert.
Therefore, based on its excretion from the body, patients
who survived 4 days or more after the discontinuation of
pregabalin were targeted. The initial and maintenance
doses were compared to doses on the package insert.
The initial dose of pregabalin (daily dose), as recom-
mended on the package insert, in the case of Ccr (mL/
min) ≥ 60 was 150 mg, in the case of 60 > Ccr ≥ 30 was
75 mg, in the case of 30 > Ccr ≥ 15 was 50 mg, and in
the case of Ccr < 15 was 25 mg. The maintenance dose
(daily dose) and highest dose (daily dose) in each case of
Ccr ≥ 60 were 300 mg and 600 mg, respectively, in each
case of 60 > Ccr ≥ 30 were 150 mg and 300 mg, respect-
ively, in each case of 30 > Ccr ≥ 15 were 75 mg and
150 mg, respectively, and in each case of Ccr < 15 were
50 mg and 75 mg, respectively.
Statistical analyses
The Mann–Whitney U-test and chi-squared test were
used to examine differences between patients prescribed
and those not prescribed pregabalin. All analyses were
performed with the Statistical Package for the Social
Sciences (version 20.0, MAKER, LOCATION). The sig-
nificance level was set at P < 0.05.
Ethical issues
This study was approved by the Ethical Review Board of
the Nippon Medical School Hospital (#28-05-580). Pa-




We obtained data on 183 patients during the study
period. Thirty-eight (20.8 %) patients were being treated
with pregabalin. Each patient was separated by the
presence or absence of a prescription for pregabalin, and
patient backgrounds are shown in Table 1. The inci-
dence of bony metastases was significantly higher in
patients administered pregabalin than in those not
taking the drug (Table 1).
Prescription for pregabalin
Twenty-five out of 38 patients were prescribed pregaba-
lin by the Department of Palliative Care. Thirty-three
out of 38 patients had been prescribed pregabalin for
pain and numbness due to cancer (Table 2).
Initial and maintenance doses of pregabalin
A comparison of the initial dose of pregabalin adminis-
tered to patients and the initial dose on the package
insert revealed that the percentage of patients started on
a smaller dose than that on the package insert in the
case of Ccr ≥ 60 was 61.1 %, in the case of 60 > Ccr ≥ 30
was 69.2 %, in the case of 30 > Ccr ≥ 15 was 66.7 %, in
the case of Ccr < 15 was 0.0 %, and for all cases was
62.9 %. The maintenance dose was compared in the
same manner. The percentage of patients started on a
smaller dose than that on the package insert in the case
of Ccr ≥ 60 was 91.7 %, in the case of 60 > Ccr ≥ 30 was
70.0 %, in the case of 30 > Ccr ≥ 15 was 0.0 %, in the case
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of Ccr < 15 was 100.0 %, and for all cases was 72.2 %
(Table 3).
Reasons for the discontinuation of pregabalin
Pregabalin was ultimately discontinued in all patients,
with the main reason being oral feeding difficulties
(81.6 %) (Table 4). Six patients discontinued pregabalin
due to side effects.
The dose of opioids before and after the discontinuation
of pregabalin
Pregabalin was discontinued in 31 patients due to oral
feeding difficulties. Twenty-three out of 31 patients sur-
vived 4 days or more after its discontinuation. For the
3 days before the discontinuation of pregabalin, the dose
of opioid drugs was increased in three patients and
unchanged in 20 patients. The dose of opioid drugs ad-
ministered 24 h after the discontinuation of pregabalin
was increased in seven patients, remained unchanged
in six patients, and was decreased in nine patients.
Furthermore, one patient discontinued opioid drugs.
This patient’s medical records showed that pain was
ameliorated by the effects of radiation therapy, and
was controlled by an intravenous injection of NSAIDs
(non-steroidal anti-inflammatory drugs).
Changes in the dose of opioid drugs administered
before and after the discontinuation of pregabalin are
Table 2 Pregabalin prescribers and reasons for its prescription








Cancer-related pain and numbness 33
Numbness due to an anti-cancer drug
treatment
1
Numbness due to radiation therapy 1
Numbness after shingles 1




Table 1 Patient characteristics
Pregabalin prescription P value
Yes No
Patients in each group (N) 38 145
Age (years, SD) 65.7 (13.8) 66.7 (10.5) 0.914a)
Male (N, %) 19 (50.0) 96 (66.2) 0.089b)
Duration of the hospital stay (day, SD) 43.8 (49.4) 38.0 (39.0) 0.668 a)
Primary sites (N)
Stomach/colon, rectum 8 61








Bone metastases (N, %) 22 (57.9) 47 (32.4) 0.014 b)
Requested reasons for palliative
care c) (N)
Pain 35 128




PS (SD) 3.3 (0.6) 3.3 (0.7) 0.829 a)
SD Standard deviation
a) Mann–Whitney U-test, b) the chi-squared test, c)Duplicate Yes
Table 3 The number of patients with initial dose and
maintenance dose (mg/day) of pregabalin
Ccr (mL/min)
Ccr ≥ 60 60 > Ccr ≥ 30 30 > Ccr ≥ 15 Ccr < 15
Initial dose a)
150 mg 7 2 0 0
75 mg 5 2 1 0
50 mg 2 2 0 0
25 mg 4 7 2 1
Maintenance dose b)
300 mg 1 3 0 0
250 mg 1 0 0 0
225 mg 2 0 0 0
150 mg 4 3 1 0
100 mg 0 1 0 0
75 mg 3 4 2 0
50 mg 0 1 0 0
25 mg 1 8 0 1
a) The initial dose (mg/day) of pregabalin in the package insert, in the case of
Ccr (mL/min) ≥ 60, was 150 mg, in the case of 60 > Ccr ≥ 30, was 75 mg, in the
case of 30 > Ccr ≥ 15, was 50 mg, and in the case of Ccr < 15, was 25 mg
b) The maintenance dose (mg/day) of pregabalin in the case of Ccr (mL/min) ≥
60 was 300 mg, in the case of 60 > Ccr ≥ 30 was 150 mg, in the case of 30 >
Ccr ≥ 15 was 75 mg, and in the case of Ccr < 15 was 50 mg
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shown in Fig. 1. The dose of opioid drugs administered
was higher in 12 (52.1 %) out of 23 patients 72 h after
the discontinuation of pregabalin than 24 h after. The
dose of opioid drugs was increased further in eight
(66.7 %) out of 12 patients 72 h after the discontinuation
of pregabalin. The dose of opioid drugs administered
was higher in 13 (56.5 %) out of 23 patients after prega-
balin was discontinued than before (Table 5).
Discussion
The results of the present study revealed that the physi-
cians of the Department of Palliative Care mainly pre-
scribed pregabalin to terminally ill cancer patients for
pain and numbness caused by cancer (Table 2). Further-
more, the incidence of bony metastases was significantly
higher in terminally ill cancer patients administered
pregabalin than in those not taking the drug (Table 1),
because pregabalin is effective in patients with the
neuropathic pain due to bony metastases.
In the present study, the initial and maintenance doses
administered were smaller than the doses described in
the package insert (Table 3). Pain control was achieved
without administering more than the recommended
dose. The incidence of the side effects of pregabalin
based on responses on an interview form was previously
reported to be between 64.5 and 82.9 %. In the present
study, the incidence of side effects was 18.8 % (Table 4),
which was very low. Previous studies reported that the
incidence of side effects was higher in the elderly and
patients with renal dysfunction [5, 6].
All patients discontinued the use of oral pregabalin
(Table 4), with the main reason being oral feeding diffi-
culties. No drugs have the same effects as pregabalin,
except for oral drugs. If patients have difficulties in oral
feeding, the doses of opioid drugs were adjusted (Table 5,
Fig. 1). The dose of opioid drugs administered 24 h after
the discontinuation of pregabalin was increased in seven
patients due to pain exacerbation. Furthermore, doses
were gradually increased over time for some patients
(Fig. 1). The dose of opioid drugs administered 24 h
after the discontinuation of pregabalin was decreased in
Fig. 1 Changes in the dose of opioid drugs before and after the discontinuation of pregabalin due to oral feeding difficulties. *: Only one
example had a lower dose than that before the discontinuation of pregabalin
Table 4 Reasons for discontinuing pregabalin
Reasons for discontinuing Number of patients (N)
Oral feeding difficulty 31
Adverse effect (sleepiness) 2
Adverse effect (renal dysfunction) 2
Adverse effect (diplopia) 1
Adverse effect (nausea) 1
To reduce the number of oral drugs 1
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nine patients due to a deterioration in the patient status
(including hepatic and renal dysfunctions) (Fig. 1). After
the discontinuation of pregabalin, the dose of opioid
drugs administered was increased in 56.5 % of patients
with oral feeding difficulties (Table 5). For the 7 days
before the discontinuation of pregabalin, the dose of
pregabalin was increased in one patients and unchanged
in 22 patients. Pregabalin is an effective treatment for
neuropathic pain that is resistant to opioid drugs.
Similar to opioid drugs, pregabalin plays an important
role in the control of pain in cancer patients [1]. Isebaba
et al. previously performed a questionnaire survey [7];
52.9–75.2 % of respondents answered that the use of ad-
juvant analgesics was effective, while 16 % answered that
the dose of opioid drugs administered may be markedly
decreased in a large number of patients. Thus, we con-
sidered it important to increase the dose of opioid drugs
because it is not possible to control pain in patients
following the discontinuation of pregabalin.
A new dosage form to continue pain control is needed.
Hospital formulations of suppositories have been investi-
gated, and their clinical application is expected [1].
Conclusion
Regarding the current status of pregabalin treatments in
terminally ill cancer patients, all patients discontinued
oral pregabalin, and the main reason was oral feeding
difficulties. This study clarified that more than 50 % of
patients increased the dose of opioid drugs after the
discontinuation of pregabalin, with doses being repeat-
edly increased for some patients. A new route of admin-
istration is required for cancer patients who are unable
to take oral medication.
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Table 5 The final dose of opioid drugs compared with that at
the time of the administration of pregabalin




Non-prescription (pain control by NSAIDs) 1
NSAIDs non-steroidal anti-inflammatory drugs
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